- FDA recommends health professionals prescribe no more than 325 mg of acetaminophen per dose
- FDA advisory panel to consider OTC status of NSAIDs
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA issues sweeping new requirements for long-acting opioids
PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.
Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.
The FDA has granted the drug priority-review status and will take action on the application in June.